Serum FGF21 levels are closely associated with early diabetic nephropathy in high-risk groups of type 2 diabetes patients, especially the circulating FGF21 value increasing more than 181 pg/mL, so that effectively targeting FGF21 therapy may contribute to early detection and prevention of diabetic microvessels complication (Esteghamati et al., 2017). This evidence concerns the gene FGF21 and type 2 diabetes mellitus.